



Encouraging Transverse Competences in the New Undergraduate degree in pharmacy: Critical News Analysis as a Tool in Teaching Pharmacology

MC RECIO, MA NOGUERA, MC MONTESINOS, A ÚBEDA, MD IVORRA, MC TERENCIO, P D'OCÓN, ML FERRÁNDIZ

The group responsible for Pedagogical Innovation in the teaching of Pharmacology at the University of Valencia has designed a new experience based on the follow-up of news of informative press and / or specialized in topics of Pharmacology and Health. AIMS: To complement the theoretical and practical education of *Pharmacology II*. To develop the critical analysis of the scientific information that is transmitted in mass media, specially in written press. To elaborate information of medicines adapted for the sanitary professional and for the patient

RESULTS AND DISCUSSION: Regarding the topics covered, the results support the selection made by teachers. The most popular topic, clearly, has been the anti-obesity treatments (Figure 2). As expected, they believe that active learning is very demanding, as they have seen that are capable of dealing with real problems and not merely academic. Therefore, the majority of respondents are very positive increasing active student participation and improving the relationship between students and student-teacher.

METHODOLOGY:

Problem Based Learning News selected (Problems)

- *New perspectives of the treatments with anticoagulants and its diffusion in different mass media.*
- *Dronedronone: a new effective anti-arrhythmic drug?* (Figures 1 and 3)
- *Critical Analysis of news related to the Pharmacology of the Obesity*, and
- *Withdrawal of rosiglitazone.*

Number of students: 16 in groups of 4.

Method: At the beginning of the course, the students choose news. In the activity of Seminar (1 Congress of Students of Pharmacy, celebrated in Valencia. In this way students from other degree courses in Pharmacy have enjoyed the most recent data of some commercial drugs (Figure 3). to which they have come after. Defence and debate with the rest of students and tutor (20-30 min).

CONCLUSION: Besides learning Pharmacology, the students have increased the confidence in themselves. They need to know how to use information sources, determine the quality and reliability of them, and to encourage critical and scientific spirit and use appropriate language and adapted depending on the audience.





Figure 2. Valoration of topics (0-10) by students (n=30)

No doubt a good stimulus always gives positive results. The participating students were encouraged to present these works to the First Congress of Students of Pharmacy, celebrated in Valencia. In this way students from other degree courses in Pharmacy have enjoyed the most recent data of some commercial drugs (Figure 3).

Figure 3. Valoration of learning method (0-5) by students (n=30)



Acknowledgements: This work is supported by a grant from the Vicerectorat de Planificació i Igualtat de la Universitat de València. Proyecto de innovación docente del grupo GID 54/2009-Farmacología "Aplicación del ABP utilizando noticias de prensa en la enseñanza de Farmacología"

CORREO FARMACEUTICO.COM
El fuerte de 'Multaq', para fibrilación auricular, está en la menor toxicidad
Es el primer antiarrítmico que sale al mercado en 25 años...
Explica los beneficios que tiene la Dronedronone.
Omite la poca efectividad que tiene respecto a la Amiodronone.
Da poca importancia a las reacciones adversas de los pacientes
"Es el primer antiarrítmico que sale al mercado en 25 años"

El mundo.es SALUD
INFORMACIÓN FIBRILACIÓN AURICULAR
Nueva opción para una arritmia común
Actualizado viernes 02/10/2009 11:41 (CET)
Ofrece una opinión positiva del fármaco
Da esperanzas a los pacientes con problemas cardiovasculares
Insinúa que es un sustitutivo de la Amiodronone.
Preguntan al director médico de Sanofi-Aventis.
Indican que los efectos adversos no son relevantes

Los Angeles Times HEALTH
Booster Shots
Highly touted heart drug Multaq not as good as generics, cardiologists say [Updated] April 5, 2010
Dronedronone, a highly touted drug targeted at atrial fibrillation and sold under the brand name Multaq, has little effect on patients with atrial fibrillation, according to a study reported Monday. It should be used only as a second-line treatment.
Opinión de los cardiólogos del hospital Cedars-Sinai Medical Center.
Dronedronone es solo la mitad de efectivo que Amiodronone.
Considera que debería usarse como segunda línea de tratamiento.
No presenta ninguna ventaja clara
Corte de 28 días de tratamiento (Drug tariff and CEMMS, march 2010):
Dronedronone 400 mg → 81,9 €
Amiodronone 200 mg → 2,4 €

Figure 1. News about Dronedronone in digital press: El Mundo, Correo Farmaceutico.com, Los Angeles Times

DRONEDRONONE: ¿UN NUEVO ANTIARRITMICO?
S. Wu, C. Primo, P. Ortega, I. Antón.
Seminario Farmacología II Grado de Farmacia.
Departament de Farmacologia
Facultat de Farmacia, Universitat de València.
Estudiantes 4º curso grado Farmacia

INTRODUCCIÓN
El fármaco Dronedronone es un antiarrítmico que pertenece a la clase de los fármacos de acción directa. Su mecanismo de acción es diferente al de los antiarrítmicos de clase I, II, III y IV. Dronedronone actúa directamente sobre el canal de potasio de la membrana celular de las células cardíacas, lo que resulta en una prolongación del tiempo de refracción efectiva y una disminución de la frecuencia cardíaca.

RESULTADOS
Estudios clínicos realizados en pacientes con fibrilación auricular paroxística. Dronedronone demostró ser eficaz y seguro en el tratamiento de la fibrilación auricular. Los resultados mostraron una reducción significativa de la frecuencia cardíaca y una mejora en los síntomas de los pacientes.

CONCLUSIONES
Dronedronone es un antiarrítmico eficaz y seguro en el tratamiento de la fibrilación auricular. Su mecanismo de acción es diferente al de los antiarrítmicos de clase I, II, III y IV. Dronedronone actúa directamente sobre el canal de potasio de la membrana celular de las células cardíacas, lo que resulta en una prolongación del tiempo de refracción efectiva y una disminución de la frecuencia cardíaca.

Figure 3. Poster derived from the project presented at the First Congress of Students of Pharmacy of Valencia.